Project Details
Description
Adherence inhibits most T2D patients from reaching treatment targets. This impacts health, quality of life and cost society. To support care teams and empower patients to self-manage, we integrate data from continuous glucose monitors, connected insulin pens and activity trackers and provide real-time, personalised treatment guidance, data-derived insights, hypoglycemia warnings and dose reminders. Methods include large-scale data collection, development of a high-fidelity T2D model and required algorithms, and clinical feasibility testing of the full solution in a telemedicine context.
The consortium consists of:
Aalborg University
Steno Diabetes Center North Denmark
Steno Diabeter Center Zealand
Novo Nordisk
Glooko
Denmarks Technical University
University of Cambridge
The consortium consists of:
Aalborg University
Steno Diabetes Center North Denmark
Steno Diabeter Center Zealand
Novo Nordisk
Glooko
Denmarks Technical University
University of Cambridge
Acronym | ADAPT-T2D |
---|---|
Status | Active |
Effective start/end date | 01/12/2019 → 01/12/2024 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Impacts
-
Greater quality of life for diabetics via warnings
Morten Hasselstrøm Jensen (Participant)
Impact: Quality of life impact
Press / Media
-
Gennemskuelig kunstig intelligens skal advare diabetikere om insulinføling
Thomas Kronborg, Ole Hejlesen & Morten Hasselstrøm Jensen
04/01/2022
1 item of Media coverage
Press/Media: Press / Media
-
Gennemskuelig kunstig intelligens skal advare diabetikere om insulinføling
Thomas Kronborg, Ole Hejlesen & Morten Hasselstrøm Jensen
10/12/2021
1 item of Media coverage
Press/Media: Press / Media